Oncology Brothers: Practice-Changing Cancer Discussions

Discussing Breast Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Stephanie Graff, Director of Breast Oncology, Associate Professor of Medicine, Lifespan Cancer Institute, Brown University. Covering three important studies: - NATALEE Phase III study of ribociclib (RIBO) + endocrine therapy (ET) in HR+ patients - SONIA challenging the need for first-line use of a CDK4/6...

Discussing the EMERALD Phase III study which resulted in the FDA approval of the first oral selective estrogen receptor degrader (SERD) after demonstrating statistically significant and clinically meaningful benefit in postmenopausal women and men, with ER+, HER2- metastatic breast cancer patients, post progression in first line with endocrine therapy and CDK4/6i. In discussion with Dr. Virginia K...

Discussing the management of Colon Cancer using the algorithm with Dr. Cathy Eng, MD, Professor of Medicine at the Vanderbilt-Ingram Cancer Center, David H. Johnson Endowed Chair in Surgical & Medical Oncology, Co-Leader Gastrointestinal Cancer Research Program, Co-Director of GI Oncology Program. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@...

Discussing AACR 2023 Highlights - focusing on 3 studies that potentially could impact our practice in the community from this conference. - AEGEAN study for Non-Small Cell Lung Cancer - Keynote 966 for Cholangiocarcinoma - SWOG S1512 for Desmoplastic Melanoma

Discussing the management of Hormone Receptor Positive Breast Cancer with Dr. Margaret Gatti-Mays, Section Chief of the Breast Medical Oncology at the Ohio State University Comprehensive Cancer Center, The James Cancer Hospital & Solove Research Institute. In our discussion with Dr. Gatti-Mays we cover the treatment algorithm of the hormone receptor-positive disease following the FDA expanding...

Discussing the management of Invasive Lobular Carcinoma with Dr. Jason Mouabbi from the MD Anderson Cancer Center. We see different histologies in hormone receptor-positive breast cancer patients - we will focus on invasive lobular carcinoma in this video. Are these patients different than one with invasive ductal carcinoma? How does the prognosis differs? Website: http://www.oncbrothers.com/ Twit...

Discussing the management using an HER 2 Neu Positive Breast Cancer algorithm with Dr. Paolo Tarantino, European Institute of Oncology, Clinical Research Fellow at the Dana-Farber Cancer institute.

Discussing the management of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) with targetable mutations using the algorithm – with Dr. Jarushka Naidoo, Professor at Royal College of Surgeons in Ireland, Adjunct Professor at Department of Oncology - Sidney Kimmel Cancer Center at The Johns Hopkins University. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contac...

Discussing the management of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) without targetable mutations using the algorithm – with Dr. Eric Singhi, Assistant Professor - University of Texas, MD Anderson Cancer Center. Website: http://www.oncbrothers.com/  Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Discussing the management of Localized Non-Small Cell Lung Cancer (NSCLC) using the algorithm – with Dr. Charu Aggarwal, Associate Director - Penn Center for Precision Medicine, Associate Professor for Lung Cancer Excellence. Website: http://www.oncbrothers.com/  Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Discussing the management using the algorithm of Small Cell Lung Cancer (SCLC) – with Dr. Estelamari Rodriguez, Associate Director of Community Outreach - Thoracic Oncology at Sylvester Comprehensive Cancer Center - University of Miami Health System. Website: http://www.oncbrothers.com/  Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Discussing the MOUNTAINEER Phase II study, which resulted in the FDA approval of the Tucatinib and Trastuzumab combination for advanced colorectal cancer HER2 positive patients. In discussion with the lead author, Dr. Tanios S. Bekaii-Saab - Medical Oncology Chief, Leader of Enterprise Wide GI Cancer Program at Mayo Clinic Comprehensive Cancer Center. Website: http://www.oncbrothers.com/ Twitter:...

Discussing GU ASCO 2023 Highlights - practice changing / informing studies with Dr. Petros Grivas, Clinical Director of Genitourinary Cancer Program, Professor, Division of Medical Oncology at Fred Hutch Cancer Center.    Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Discussing the management using the algorithm of Prostate Cancer – with Dr. Neeraj Agarwal, Director of Genitourinary Oncology Program - Professor of Medicine at Huntsman Cancer Institute at University of Utah. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Discussing the EMERALD Phase III study which resulted in the FDA approval of the first oral selective estrogen receptor degrader (SERD) after demonstrating statistically significant and clinically meaningful benefit in postmenopausal women and men, with ER+, HER2- metastatic breast cancer patients, post progression in first line with endocrine therapy and CDK4/6i. In discussion with the lead autho...

Discussing GI ASCO 2023 Highlights - practice changing/informing studies with Dr. Mark Lewis, a Cancer Survivor, Director of GI Oncology at Intermountain Healthcare. SPOTLIGHT - Zolbetuximab with mFOLFOX6 Meets Primary Endpoint NAPOLI3 - Randomized Phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metas...

The NICHE-2 study offered neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer patients, resulting in a major pathologic response in 95% of patients and 67% pCR. In discussion with the lead author, Dr. Myriam Chalabi - Medical Oncologist at the Netherlands Cancer Institute.   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Conta...

Discussing the management of Bladder Cancer using an algorithm – with Dr. Andrea Apolo, Chief of Bladder Cancer - Genitourinary Malignancy at the National Cancer Institute.  Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Discussing the management using the algorithm of Kidney Cancer or Renal Cell Cancer (RCC) – with Dr. Elizabeth Plimack, Deputy Director, Fox Chase Cancer Center – Temple Health, Director – Genitourinary Clinical Research, Temple University Health System. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Discussing the DESTINY-Breast04 study which resulted in a paradigm shift, with the introduction of low HER2 positive breast cancer, and further approval of Trastuzumab Deruxtecan (T-DXd). In discussion with the lead author, Dr. Shanu Modi - Professor of Medicine at Memorial Sloan Kettering Cancer Center. Website: http://www.oncbrothers.com/  Twitter: https://twitter.com/oncbrothers  Cont...

Discussing Triple Negative Breast Cancer (TNBC) from the SABCS 2022 - Practice changing studies with Dr. Maryam Lustberg, Director of Breast Cancer Center, Chief of Breast Medical Oncology, Associate Professor of Internal Medicine at Yale Cancer Center - Yale School of Medicine. CME Information link: https://integrityce.com/courses/clinical-updates-from-san-antonio-triple-negative-breast-cancer-ne...

Discussing practice-changing studies from the American Society of Hematology (ASH) 2022 with Dr. Aaron Goodman "Papa Heme", Associate Professor of Medicine at UC San Diego Health - San Diego Hospital. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Discussing HER 2 neu Positive (HER2+) from SABCS 2022 - Practice changing studies with Dr. Erika Hamilton, Director of Breast & Gynecologic Cancer Research, Sarah Cannon Research Institute. CME Information link: https://integrityce.com/courses/clinical-updates-from-san-antonio-her2-and-her2-low-breast-cancer/  Website: http://www.oncbrothers.com/  Twitter: https://twitter.com/oncbrot...

Discussing new SERDs in Hormone Receptor Positive (HR+) from SABCS 2022 - Practice changing studies with Dr. Stephanie Graff, Director of Breast Oncology, Associate Professor of Medicine at Lifespan Cancer Institute, Brown University; Medical Advisor, Dr. Susan Love Foundation  CME information and credit available at: https://integrityce.com/courses/clinical-updates-from-san-antonio-her2-adva...

Discussing Hormone Receptor Positive (HR+) Highlights from SABCS 2022 on usage of CDK4/6 inhibitors - Practice changing studies with Dr. Sara Tolaney, Chief - Division of Breast Oncology at Dana-Farber and Associate Professor at Harvard Medical School. CME information and credit available at: https://integrityce.com/courses/clinical-updates-from-san-antonio-hr-her2-breast-cancer-cdk-4-6-inhibitors...